Replies to post #138279 on Biotech Values

[jellybean]

So then you aren't buying the conventional wisdom of HCV being a $20B market?

[mcbio]

Not if the IP is worth a pittance in terms of royalties. Say for the sake of discussion that IDIX can get 1% of 7977’s US sales until the patent in question expires; the stock would still be way overvalued, IMHO.

I had the same type of thoughts as dewophile on the IDIX PR, thinking this could have value for IDIX if this affords them some right to royalties on 7977. The PR does state IDIX is the senior party and Pharmasset is the junior party with the requirement to show burden of proof. So, if the patent does have relevance to 7977, this might bode well for IDIX but your point is well taken on how meaningful any potential royalties due IDIX would be. At >$1B market cap nowadays, it would have to be a meaningful percentage on royalties of 7977 to presumably move the dial for IDIX. And I don't know what the normal type of settlement is in these types of IP issues, assuming the patents relate to 7977 and Pharmasset is unsuccessful in defending its IP.